D Michelson

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study
    D Michelson
    Lilly Research Laboratories and Indiana University School of Medicine, Indianapolis, Indiana, USA
    Pediatrics 108:E83. 2001
  2. ncbi request reprint Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 159:1896-901. 2002
  3. ncbi request reprint Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial
    David Michelson
    Lilly Research Laboratories, Lilly Corporate Center 6026, Indianapolis, IN 46285, USA
    J Psychiatr Res 36:147-52. 2002
  4. ncbi request reprint Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment
    D Michelson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Sex Marital Ther 27:289-302. 2001
  5. ncbi request reprint Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial
    D Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Br J Psychiatry 176:363-8. 2000
  6. ncbi request reprint Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment
    D Michelson
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Psychoneuroendocrinology 25:169-77. 2000
  7. ncbi request reprint Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention
    D Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 157:239-43. 2000
  8. ncbi request reprint Changes in weight during a 1-year trial of fluoxetine
    D Michelson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Psychiatry 156:1170-6. 1999
  9. ncbi request reprint Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group
    D Michelson
    Medical University of South Carolina, Charleston, USA
    Am J Psychiatry 155:1570-7. 1998
  10. ncbi request reprint Pathophysiologic and somatic investigations of hypothalamic-pituitary-adrenal axis activation in patients with depression
    D Michelson
    Clinical Neuroendocrinology Branch, National Institutes of Mental Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 840:717-22. 1998

Detail Information

Publications44

  1. ncbi request reprint Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study
    D Michelson
    Lilly Research Laboratories and Indiana University School of Medicine, Indianapolis, Indiana, USA
    Pediatrics 108:E83. 2001
    ..It is thought to act via blockade of the presynaptic norepinephrine transporter in the brain. We assessed the efficacy of 3 doses of atomoxetine compared with placebo in children and adolescents with ADHD...
  2. ncbi request reprint Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 159:1896-901. 2002
    ..The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)...
  3. ncbi request reprint Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial
    David Michelson
    Lilly Research Laboratories, Lilly Corporate Center 6026, Indianapolis, IN 46285, USA
    J Psychiatr Res 36:147-52. 2002
    ..Many agents have been proposed as potential treatments for SSRI-associated sexual dysfunction, but few placebo-controlled trials have been reported...
  4. ncbi request reprint Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment
    D Michelson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Sex Marital Ther 27:289-302. 2001
    ..Among patients who report worsening, effects may be most pronounced on orgasm. Deterioration in sexual function does not appear to be a late-onset drug-specific event, but is strongly related to worsening depressive symptoms...
  5. ncbi request reprint Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial
    D Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Br J Psychiatry 176:363-8. 2000
    ..Abrupt interruption of therapy with selective serotonin reuptake inhibitors (SSRIs) has been associated with somatic and psychological symptoms...
  6. ncbi request reprint Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment
    D Michelson
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Psychoneuroendocrinology 25:169-77. 2000
    ..These data suggest that some activation of physiologic stress-responses may accompany symptom increases during treatment interruption of shorter half-life agents...
  7. ncbi request reprint Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention
    D Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 157:239-43. 2000
    ..The authors evaluated the efficacy of buspirone and amantadine in the treatment of sexual dysfunction associated with fluoxetine administration...
  8. ncbi request reprint Changes in weight during a 1-year trial of fluoxetine
    D Michelson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Psychiatry 156:1170-6. 1999
    ..Weights were assessed for patients whose depressive symptoms had disappeared with acute fluoxetine treatment. Patients were then randomly assigned to continuation treatment with fluoxetine or placebo...
  9. ncbi request reprint Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group
    D Michelson
    Medical University of South Carolina, Charleston, USA
    Am J Psychiatry 155:1570-7. 1998
    ..The authors studied the efficacy of fluoxetine treatment in panic disorder and measured the relative contributions of changes in symptoms to overall improvement...
  10. ncbi request reprint Pathophysiologic and somatic investigations of hypothalamic-pituitary-adrenal axis activation in patients with depression
    D Michelson
    Clinical Neuroendocrinology Branch, National Institutes of Mental Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 840:717-22. 1998
    ..05). Taken together, these studies suggest HPA axis dysregulations demonstrated in preclinical models of autoimmune and inflammatory illness also occur in human illness and may have important and lasting somatic sequelae...
  11. ncbi request reprint Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans
    D Michelson
    Clinical Neuroendocrinology Branch, National Institute of Mental Health, Bethesda, Maryland, USA
    J Clin Endocrinol Metab 82:2601-6. 1997
    ..These data are consistent with preclinical findings and support the hypothesis that imipramine has an intrinsic effect on central components of HPA axis function, potentially related to its therapeutic effects...
  12. ncbi request reprint Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial
    D Michelson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 179:514-8. 2001
    ..CONCLUSIONS: Fluoxetine at a dose of 20 mg daily is safe and efficacious in reducing symptoms of panic disorder. Patients who fail to obtain a satisfactory response at 20 mg daily may benefit from further dose increases...
  13. ncbi request reprint Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6
    R DeRijk
    Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 82:2182-91. 1997
    ..The resistance of IL-6 production to glucocorticoid suppression is compatible with data suggesting an antiinflammatory as well as a proinflammatory action for this cytokine...
  14. ncbi request reprint The stress response in critical illness
    D Michelson
    Clinical Neuroendocrinology Branch, National Institute of Mental Health, Bethesda, MD 20892
    New Horiz 2:426-31. 1994
    ....
  15. ncbi request reprint ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument
    S Zhang
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Int J Methods Psychiatr Res 14:186-201. 2005
    ..Overall, the data from this study support the use of the ADHD RS as a clinician-rated instrument for assessing the severity of ADHD symptoms in children and adolescents in Europe...
  16. ncbi request reprint Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder
    Stephen V Faraone
    Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, New York 13210, USA
    J Child Adolesc Psychopharmacol 15:664-70. 2005
    ..The aim of this study was to assess the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, for executive functioning in adults with attention-deficit/hyperactivity disorder (ADHD)...
  17. ncbi request reprint A comparison of North American versus non-North American ADHD study populations
    Jan K Buitelaar
    Dept of Psychiatry, Academic Centre for Child and Adolescent Psychiatry, University Medical Centre St Radboud, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Eur Child Adolesc Psychiatry 15:177-81. 2006
    ..This supports the practice of generalizing results from treatment studies across geographies...
  18. ncbi request reprint Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder
    Philip Hazell
    Child and Youth Mental Health Service, University of Newcastle, Locked Bag 1014, Wallsend, NSW 2287, Australia
    Eur Child Adolesc Psychiatry 15:105-10. 2006
    ..To examine the influence of comorbid oppositional defiant disorder (ODD) on the relative risk (RR) of relapse during 9 months of treatment with atomoxetine for attention-deficit/hyperactivity disorder (ADHD)...
  19. ncbi request reprint Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity
    Thomas J Spencer
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:415-20. 2006
    ....
  20. ncbi request reprint A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year
    Jan K Buitelaar
    University Medical Center St Radboud, Nijmegen, The Netherlands
    Biol Psychiatry 61:694-9. 2007
    ..The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n = 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD)...
  21. ncbi request reprint Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder
    Jeffrey H Newcorn
    Mount Sinai Medical Center, Department of Psychiatry, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
    Pediatrics 118:e1701-6. 2006
    ..However, lower doses could be effective during maintenance treatment, which would reduce drug exposure and potential problems related to tolerability during chronic treatment...
  22. ncbi request reprint CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD
    David Michelson
    Lilly Research Laboratories, Indianapolis, USA
    J Am Acad Child Adolesc Psychiatry 46:242-51. 2007
    ..Variations in plasma atomoxetine exposures can occur because of genetic variation or as a consequence of coadministration with drugs that inhibit CYP2D6...
  23. ncbi request reprint Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model
    Sandeep T Patil
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Proteome Res 6:955-66. 2007
    ..These studies suggest that identification of changes in the CSF proteome associated with the administration of centrally active drugs is feasible, and may be of value in the development of new drugs, as well as broader clinical research...
  24. ncbi request reprint Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:582-7. 2007
    ..Addition of a noradrenergic intervention in patients poorly or partially responsive to SSRIs may improve outcomes, but few well-controlled studies testing this hypothesis have been reported...
  25. ncbi request reprint High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Am Acad Child Adolesc Psychiatry 46:1128-37. 2007
    ..To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD)...
  26. ncbi request reprint The reliability and validity of self- and investigator ratings of ADHD in adults
    Lenard A Adler
    New York University School of Medicine, New York, NY 10016, USA
    J Atten Disord 11:711-9. 2008
    ....
  27. doi request reprint Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai Medical Center, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:721-30. 2008
    ....
  28. doi request reprint Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders
    Timothy E Wilens
    Massachusetts General Hospital, 55 Fruit Street, YAW 6900, Boston, MA 02114, USA
    Drug Alcohol Depend 96:145-54. 2008
    ..The study aim was to determine if atomoxetine was superior to placebo in improving ADHD and alcohol use in recently abstinent adults with ADHD and comorbid alcohol use disorder...
  29. ncbi request reprint Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
    Christopher J Kratochvil
    Department of Psychiatry, Nebraska Medical Center, Omaha 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:915-24. 2005
    ..The authors assessed the safety and effectiveness of atomoxetine monotherapy compared with combined atomoxetine/fluoxetine therapy in a population of children and adolescents with ADHD and concurrent symptoms of depression or anxiety...
  30. ncbi request reprint Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial
    Christopher J Kratochvil
    University of Nebraska Medical Center, USA
    J Am Acad Child Adolesc Psychiatry 41:776-84. 2002
    ..Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.)..
  31. ncbi request reprint Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment
    Michael E Henry
    Brain Imaging Center, McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts 02478, USA
    Biol Psychiatry 53:100-5. 2003
    ..We hypothesized that brain regions implicated in depression, with extensive serotonergic innervation, would exhibit changes in activity associated with emergence of symptoms following drug discontinuation...
  32. ncbi request reprint Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
    David Michelson
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 53:112-20. 2003
    ..To assess the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, we conducted two large, multicenter treatment trials...
  33. ncbi request reprint Drug development process for a product with a primary pediatric indication
    Albert J Allen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 63:44-9. 2002
    ....
  34. ncbi request reprint Cardiovascular effects of atomoxetine in children, adolescents, and adults
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Drug Saf 26:729-40. 2003
    ..Adverse effects on the cardiovascular system, including abnormalities in heart rate, blood pressure, or cardiac rhythm have been associated with several noradrenergic medications...
  35. ncbi request reprint Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis IN 46285, USA
    J Clin Psychopharmacol 24:30-5. 2004
    ..It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects. Tapering of doses is not necessary when atomoxetine is discontinued...
  36. ncbi request reprint Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine
    Melissa J Joliat
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychiatry 65:373-8. 2004
    ..We report a retrospective pooled analysis of 2 studies to assess the effect of associated anxiety on the efficacy of fluoxetine in the continuation treatment phase of MDD...
  37. ncbi request reprint The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder
    Louis S Matza
    MEDTAP International, Inc, Bethesda, Maryland, USA
    J Dev Behav Pediatr 25:166-74. 2004
    ..The findings suggest that HRQL instruments can add important information to efficacy measures in clinical trials of ADHD treatment...
  38. ncbi request reprint Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 43:896-904. 2004
    ..Attention-deficit/hyperactivity disorder (ADHD) is typically treated over extended periods; however, few placebo-controlled, long-term studies of efficacy have been reported...
  39. ncbi request reprint Atomoxetine--treatment of attention deficit hyperactivity disorder: beyond stimulants
    Christine Thomason
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Drugs Today (Barc) 40:465-73. 2004
    ..This paper reviews atomoxetine's chemistry and putative mechanism of action, as well as its clinical pharmacokinetics, metabolism, and efficacy and safety in acute clinical trials. (c) 2004 Prous Science. All rights reserved...
  40. ncbi request reprint A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
    Jan K Buitelaar
    Department of Psychiatry, University Medical Center Nijmegen, 9101, 6500, HB Nijmegen, The Netherlands
    Eur Child Adolesc Psychiatry 13:249-57. 2004
    ..The aim of this study was to study treatment response to atomoxetine in a large, multicenter study of non-North American patients with ADHD...
  41. ncbi request reprint Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai School of Medicine, New York 10029, USA
    J Am Acad Child Adolesc Psychiatry 44:240-8. 2005
    ..To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine...
  42. ncbi request reprint Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis
    Lenard A Adler
    New York University, New York, USA
    J Clin Psychiatry 66:294-9. 2005
    ..These symptoms have largely been defined in the childhood population, but the course of the condition and expression in the adult population are not as well characterized...
  43. ncbi request reprint Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Massachusetts General Hospital, Boston, MA 02114, USA
    Pediatrics 116:e74-80. 2005
    ..This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder...
  44. ncbi request reprint Training raters to assess adult ADHD: reliability of ratings
    Lenard A Adler
    New York University School of Medicine, New York, NY 10016, USA
    J Atten Disord 8:121-6. 2005
    ..For the ADHDRS-IV-Inv, rater agreement was moderate, and reliability, as measured by Cronbach's alpha, was substantial. The data indicate that clinicians can be trained to reliably evaluate ADHD in adults using the ADHDRS-IV-Inv...